The estimated Net Worth of Jeffrey Hager is at least $4.63 Million dollars as of 26 July 2019. Dr Hager owns over 5,197 units of IDEAYA Biosciences stock worth over $4,628,279 and over the last 5 years he sold IDYA stock worth over $0.
Dr has made over 2 trades of the IDEAYA Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 5,197 units of IDYA stock worth $22,399 on 26 July 2019.
The largest trade he's ever made was exercising 15,773 units of IDEAYA Biosciences stock on 19 June 2019 worth over $67,982. On average, Dr trades about 10,485 units every 19 days since 2019. As of 26 July 2019 he still owns at least 127,853 units of IDEAYA Biosciences stock.
You can see the complete history of Dr Hager stock trades at the bottom of the page.
Dr. Jeffrey Hager Ph.D. is the Co-Founder & Member of the Scientific Advisory Board at IDEAYA Biosciences.
Dr D is 56, he's been the Co-Founder & Member of the Scientific Advisory Board of IDEAYA Biosciences since . There are 6 older and 10 younger executives at IDEAYA Biosciences. The oldest executive at IDEAYA Biosciences, Inc. is Wendy Yarno, 65, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at IDEAYA Biosciences have traded over $13,169,580 worth of IDEAYA Biosciences stock and bought 2,220,527 units worth $22,722,236 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Timothy M Shannon, and X L.P.Canaan Partners X Llc.... On average, IDEAYA Biosciences executives and independent directors trade stock every 29 days with the average trade being worth of $2,196,906. The most recent stock trade was executed by Jason Throne on 27 June 2024, trading 53,484 units of IDYA stock currently worth $415,571.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences executives and other stock owners filed with the SEC include: